It appears Hsp90 drugs may have a role in combating prostate cancer, kidney cancer, and other urologic cancers.
Renal Cell Carcinoma
Patients with renal cell carcinoma (RCC) who have not responded to prior therapy may soon have a new treatment option.
A major step is now occurring in the advancement of precision medicine in the treatment of cancer. A record number of cancer patients are now being enrolled in a trial that is like none other before and marks a new era in treating cancer.
The US Food and Drug Administration (FDA) on July 29, 2015, granted a breakthrough therapy designation to Eisai's lenvatinib (Lenvima), which is an orally administered, multiple receptor tyrosine kinase (RTK) inhibitor.
A 20-year-old young man presents with hypertension and a left kidney mass. After further evaluation, a biopsy is performed. What is your diagnosis?
For the first time, researchers have found that a checkpoint inhibitor may result in a survival advantage in advanced renal cell carcinoma (RCC), according to new data from an open-label, randomized, phase III study.
A 47-year-old man presents with pain in the right flank. A kidney mass is found on imaging.
Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) have created a tiny device that can deliver cancer therapies directly to the tumor site. What's more, this technology could potentially treat chemotherapy-induced kidney failure.
A 63-year-old man presents with a mass in the left kidney. After further evaluation, a biopsy is performed. What is your diagnosis?
Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict response to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).